MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 14, 2005; DOI: 10.1124/mol.105.020529


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.020529v1
69/3/796    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tyson-Capper, A. J
Right arrow Articles by Europe-Finner, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tyson-Capper, A. J
Right arrow Articles by Europe-Finner, G. N.


Received for publication November 2, 2005.
Revised December 13, 2005.
Accepted for publication December 13, 2005.

Novel Targeting Of COX-2 pre-mRNA Using Antisense Morpholino Oligonucleotides Directed To The 3' Acceptor And 5' Donor Splice Sites Of Exon 4: Suppression Of COX-2 Activity In Human Amnion-Derived WISH And Myometrial Cells

Alison J Tyson-Capper 1* G. Nicholas Europe-Finner 1

1 University of Newcastle

* Address correspondence to: E-mail: a.j.tyson-capper{at}ncl.ac.uk

Abstract

Increased expression of COX-2 has been implicated in the onset of both term and preterm labour. In this context both selective and non-selective COX-2 inhibitors have been used in clinical trials to determine their efficacy in delaying preterm labour. However recent evidence indicates that these tocolytics may have potential adverse fetal and maternal side effects. Consequently, the development of more specific and non-toxic agents to inhibit COX-2 needs to be considered. We have evaluated whether antisense morpholino oligonucleotides have therapeutic potential in inhibiting COX-2 by specifically targeting both the 3' and 5 ' acceptor and donor sites of exon 4 of its pre-mRNA sequence. Confocal microscopy on 'live' cells illustrated high levels of penetrance of antisense morpholino oligonucleotides using the Endo-Porter formula (Gene-Tools, LLC) with delivery efficiencies of 82% and 78% respectively in amnion-derived WISH and myometrial cells. Substantial inhibition by the morpholino oligonucleotides of COX-2 expression, induced by LPS administration, was observed at both the mRNA and protein level. Loss of enzymic activity of COX-2 was confirmed using a sensitive COX enzyme activity assay which reflects the rate of conversion of arachidonic acid to PGH2. Our results indicate that antisense morpholino oligonucleotides significantly inhibit expression and activity of this enzyme in in vitro cultures of amnion-WISH and myometrial cells. The potential thus exists that a similar approach can be mimicked in vivo to produce a highly specific and non-toxic strategy to inhibit COX-2 activity with its subsequent effects on the better management of preterm labour and other inflammatory conditions.


Key words: Regulation of gene expression, Cyclooxygenases, Antisense





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics